USOR 23332 - STAR Ph2 study of AK117 in combo with azacitidine in patients with myelodysplastic syndromes

A randomized, double-blind, placebo-controlled, multicenter phase 2 study of AK117/placebo in combination with azacitidine in patients with newly diagnosed higher-risk myelodysplastic syndrome (AK117-205)

Disease Types: Solid Tumor, STAR: Selected Trials Available for Accelerated Four Week Rollout

Available at: Arlington Heights